Flectortissugel Heparin sprain 3 plasters is a medication in plaster form, recommended for ankle sprains.
Flector Tissugel Heparin plasters contain 2 active ingredients:
- Diclofenac epolamine, a non-steroidal anti-inflammatory drug (NSAID) used to soothe pain and reduce inflammation associated with sprains and other injuries.
- Topicalheparin sodium, an anti-inflammatory and anti-oedematous active ingredient.
Directions for use Flectortissugel Sprain Heparin 3 plasters
Dosage
ADULTS: 1 application per day.
Use FLECTOR TISSUGEL HEPARINE for the shortest possible time.
Application of FLECTOR TISSUGEL HEPARINE should not exceed 3 days. If there is no improvement after 3 days, a physician should be consulted.
Pediatric population
In the absence of specific studies, the use of FLECTOR TISSUGEL HEPARINE is not recommended in children.
Elderly
This drug should be used with caution in the elderly (see Warnings and Precautions).
Hepatic or renal insufficiency
For use of FLECTOR TISSUGEL HEPARINE in patients with hepatic or renal insufficiency, see Warnings and Precautions for Use.
Method of administration
Cut the plaster envelope where indicated.
Remove the plaster, peel off the plastic film protecting the adhesive surface and apply the plaster to the painful area or joint. If necessary, the plaster can be held in place with elastic netting.
Close the envelope carefully with the zipper.
The plaster must be used intact.
Precautions for use Flectortissugel Heparin sprain 3 plasters
Contraindications:
Hypersensitivity to the active substance or to any of the excipients listed under Excipients.
- Pregnancy, from the beginning of the 6th month (beyond 24 weeks of amenorrhea) (see Fertility, pregnancy and breast-feeding),
- Injured skin, whatever the lesion: oozing dermatitis, eczema, infected lesions, burns or wounds.
- Patients with active peptic ulcers.
- In children.
Precautions for use:
The plaster must not come into contact with eyes/mucous membranes or be applied to eyes or mucous membranes.
Do not use under an occlusive dressing. However, for the treatment of sprains and strains, a compression bandage may be used.
If you develop a rash after applying FLECTOR TISSUGEL HEPARINE, discontinue treatment immediately.
The concomitant administration of drugs containing diclofenac or other NSAIDs, either topically or systemically, should be avoided.
Although the occurrence of systemic adverse reactions is rare, FLECTOR TISSUGEL HEPARINE should be used with caution in patients with impaired cardiac, renal or hepatic function, and in patients with a history of gastrointestinal ulcers, inflammatory bowel disease or gastrointestinal bleeding. Non-steroidal anti-inflammatory drugs should be used with particular caution in the elderly, who are more prone to adverse reactions.
This medicine contains methyl parahydroxybenzoate and propyl parahydroxybenzoate. It may cause allergic reactions (possibly delayed). This medicine contains 420 mg propylene glycol, which may cause skin irritation.
This medicine contains a fragrance containing the following allergens which may cause allergic reactions: benzyl salicylate, alpha amylcinnamic aldehyde, hydroxycitronellal and cinnamic alcohol. To reduce the risk of photosensitization, patients should be advised to avoid exposure to solar radiation (sunlight or UV booths).
Bronchospasm may occur in patients with bronchial asthma, allergic disease or allergy to acetylsalicylic acid or other NSAIDs, or a history of these conditions. FLECTOR TISSUGEL HEPARINE should be used with caution in patients with or without chronic asthma, in whom attacks of asthma, urticaria or acute rhinitis are provoked by aspirin or other non-steroidal anti-inflammatory drugs (see Contraindications).
Pregnancy and lactation :
Pregnancy
Inhibition of prostaglandin synthesis by NSAIDs may affect the course of pregnancy and/or the development of the embryo or fetus.
Risks associated with 1st trimester use
Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis, following treatment with a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformation increased from less than 1% in the general population, to approximately 1.5% in people exposed to NSAIDs. The risk appears to increase with dose and duration of treatment. In animals, administration of a prostaglandin synthesis inhibitor has been shown to cause increased pre- and post-implantation loss and embryo-fetal lethality. In addition, a higher incidence of certain malformations, including cardiovascular, has been reported in animals given a prostaglandin synthesis inhibitor during the organogenesis phase of gestation.
Risks associated with use from 12 weeks of amenorrhea to birth:
- From the 12th week of amenorrhea until birth, all NSAIDs, by inhibiting prostaglandin synthesis, can expose the fetus to renal impairment:
- in utero, as early as 12 weeks of amenorrhea (start of fetal diuresis): oligohydramnios (usually reversible on discontinuation of treatment), or anohydramnios, particularly with prolonged exposure.
- at birth, renal insufficiency (reversible or not) may persist, particularly in cases of late and prolonged exposure (with a risk of delayed severe hyperkalemia).Risks associated with use beyond the 24th week of amenorrhea and up to birth:
Beyond the 24th week of amenorrhea, NSAIDs may expose the fetus to cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension). Constriction of the ductus arteriosus can occur from the beginning of the 6th month (beyond the 24th week of amenorrhea) and can lead to fetal or neonatal right heart failure, or even fetal death in utero. This risk is all the greater the closer to term the drug is taken (less reversibility). This effect exists even when a single dose is taken.
At the end of pregnancy, both mother and newborn may experience :
- prolonged bleeding time, due to an anti-aggregation action which may occur even after very low doses of the drug have been administered;
- inhibition of uterine contractions, leading to delayed term or prolonged delivery:
Unless absolutely necessary, this drug should not be prescribed to women contemplating pregnancy or during the first 5 months of pregnancy (first 24 weeks of amenorrhea). If this drug is administered to a woman wishing to become pregnant or who is less than 6 months pregnant, the dose should be as low as possible and the duration of treatment as short as possible. Prolonged use is strongly discouraged.
From the beginning of the 6th month (beyond 24 weeks of amenorrhea): any intake of this drug, even punctual, is contraindicated. Inadvertent use after this date warrants cardiac, renal, fetal and/or neonatal monitoring, depending on the term of exposure. The duration of this monitoring should be adapted to the compound's elimination half-life
Breast-feeding
As A.I.N.S. is excreted in breast milk, this drug is not recommended for nursing mothers.
In the event of breast-feeding, this drug should never be applied to the breasts.
Fertility
As with all NSAIDs, the use of this drug may temporarily impair female fertility by affecting ovulation; it is therefore not recommended for women wishing to conceive a child. In women experiencing difficulties conceiving, or undergoing fertility tests, discontinuation of treatment should be considered.
Effects on ability to drive and use machines:
Although the occurrence of such effects is highly unlikely when using skin preparations such as FLECTOR TISSUGEL HEPARINE, patients who have previously experienced dizziness or other Central Nervous System disorders while taking NSAIDs should refrain from driving vehicles or operating machinery.
Composition Flectortissugel Heparin sprain 3 plasters
medicated plaster (white to pale yellow gel spread evenly on a non-woven backing) : Diclofenac epolamine, i.e. Diclofenac sodium 1 g/100 g, Heparin sodium 40,000 IU/100 g.
non-woven backing: Polyester. adhesive layer (active gel) : Gelatin, Povidone K 90, Liquid sorbitol (non-crystallizable), Heavy kaolin, Titanium dioxide (E 171), Propylene glycol, Methyl parahydroxybenzoate (E 218), Propyl parahydroxybenzoate (E 216), Disodium edetate (E 385), Tartaric acid, Aluminium glycinate, Sodium carmellose, Sodium polyacrylate, 1,3-butylene glycol, Polysorbate 80, Parfum Dalin PH, (Propylene glycol, Benzyl salicylate, Phenylethyl alcohol, Alpha amylcinnamic aldehyde, Hydroxycitronellal, Phenylethyl phenylacetate, Cinnamyl acetate, Benzyl acetate, Terpineol, Cinnamic alcohol, Cyclamenaldehyde), Purified water.
protective film: Polypropylene.
Each 10 cm x 14 cm medicated plaster contains 14 g gel containing 140 mg sodium diclofenac as diclofenac epolamine and 5600 IU heparin sodium.
Notable excipients: propylene glycol (420 mg), methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216) and Dalin PH fragrance containing benzyl salicylate, alpha amylcinnamic aldehyde, hydroxycitronellal and cinnamic alcohol.
Flectortissugel Heparin sprain 3 plasters is a medication in plaster form, recommended for ankle sprains.
Flector Tissugel Heparin plasters contain 2 active ingredients:
- Diclofenac epolamine, a non-steroidal anti-inflammatory drug (NSAID) used to soothe pain and reduce inflammation associated with sprains and other injuries.
- Topicalheparin sodium, an anti-inflammatory and anti-oedematous active ingredient.
Directions for use Flectortissugel Sprain Heparin 3 plasters
Dosage
ADULTS: 1 application per day.
Use FLECTOR TISSUGEL HEPARINE for the shortest possible time.
Application of FLECTOR TISSUGEL HEPARINE should not exceed 3 days. If there is no improvement after 3 days, a physician should be consulted.
Pediatric population
In the absence of specific studies, the use of FLECTOR TISSUGEL HEPARINE is not recommended in children.
Elderly
This drug should be used with caution in the elderly (see Warnings and Precautions).
Hepatic or renal insufficiency
For use of FLECTOR TISSUGEL HEPARINE in patients with hepatic or renal insufficiency, see Warnings and Precautions for Use.
Method of administration
Cut the plaster envelope where indicated.
Remove the plaster, peel off the plastic film protecting the adhesive surface and apply the plaster to the painful area or joint. If necessary, the plaster can be held in place with elastic netting.
Close the envelope carefully with the zipper.
The plaster must be used intact.
Precautions for use Flectortissugel Heparin sprain 3 plasters
Contraindications:
Hypersensitivity to the active substance or to any of the excipients listed under Excipients.
- Pregnancy, from the beginning of the 6th month (beyond 24 weeks of amenorrhea) (see Fertility, pregnancy and breast-feeding),
- Injured skin, whatever the lesion: oozing dermatitis, eczema, infected lesions, burns or wounds.
- Patients with active peptic ulcers.
- In children.
Precautions for use:
The plaster must not come into contact with eyes/mucous membranes or be applied to eyes or mucous membranes.
Do not use under an occlusive dressing. However, for the treatment of sprains and strains, a compression bandage may be used.
If you develop a rash after applying FLECTOR TISSUGEL HEPARINE, discontinue treatment immediately.
The concomitant administration of drugs containing diclofenac or other NSAIDs, either topically or systemically, should be avoided.
Although the occurrence of systemic adverse reactions is rare, FLECTOR TISSUGEL HEPARINE should be used with caution in patients with impaired cardiac, renal or hepatic function, and in patients with a history of gastrointestinal ulcers, inflammatory bowel disease or gastrointestinal bleeding. Non-steroidal anti-inflammatory drugs should be used with particular caution in the elderly, who are more prone to adverse reactions.
This medicine contains methyl parahydroxybenzoate and propyl parahydroxybenzoate. It may cause allergic reactions (possibly delayed). This medicine contains 420 mg propylene glycol, which may cause skin irritation.
This medicine contains a fragrance containing the following allergens which may cause allergic reactions: benzyl salicylate, alpha amylcinnamic aldehyde, hydroxycitronellal and cinnamic alcohol. To reduce the risk of photosensitization, patients should be advised to avoid exposure to solar radiation (sunlight or UV booths).
Bronchospasm may occur in patients with bronchial asthma, allergic disease or allergy to acetylsalicylic acid or other NSAIDs, or a history of these conditions. FLECTOR TISSUGEL HEPARINE should be used with caution in patients with or without chronic asthma, in whom attacks of asthma, urticaria or acute rhinitis are provoked by aspirin or other non-steroidal anti-inflammatory drugs (see Contraindications).
Pregnancy and lactation :
Pregnancy
Inhibition of prostaglandin synthesis by NSAIDs may affect the course of pregnancy and/or the development of the embryo or fetus.
Risks associated with 1st trimester use
Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis, following treatment with a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformation increased from less than 1% in the general population, to approximately 1.5% in people exposed to NSAIDs. The risk appears to increase with dose and duration of treatment. In animals, administration of a prostaglandin synthesis inhibitor has been shown to cause increased pre- and post-implantation loss and embryo-fetal lethality. In addition, a higher incidence of certain malformations, including cardiovascular, has been reported in animals given a prostaglandin synthesis inhibitor during the organogenesis phase of gestation.
Risks associated with use from 12 weeks of amenorrhea to birth:
- From the 12th week of amenorrhea until birth, all NSAIDs, by inhibiting prostaglandin synthesis, can expose the fetus to renal impairment:
- in utero, as early as 12 weeks of amenorrhea (start of fetal diuresis): oligohydramnios (usually reversible on discontinuation of treatment), or anohydramnios, particularly with prolonged exposure.
- at birth, renal insufficiency (reversible or not) may persist, particularly in cases of late and prolonged exposure (with a risk of delayed severe hyperkalemia).Risks associated with use beyond the 24th week of amenorrhea and up to birth:
Beyond the 24th week of amenorrhea, NSAIDs may expose the fetus to cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension). Constriction of the ductus arteriosus can occur from the beginning of the 6th month (beyond the 24th week of amenorrhea) and can lead to fetal or neonatal right heart failure, or even fetal death in utero. This risk is all the greater the closer to term the drug is taken (less reversibility). This effect exists even when a single dose is taken.
At the end of pregnancy, both mother and newborn may experience :
- prolonged bleeding time, due to an anti-aggregation action which may occur even after very low doses of the drug have been administered;
- inhibition of uterine contractions, leading to delayed term or prolonged delivery:
Unless absolutely necessary, this drug should not be prescribed to women contemplating pregnancy or during the first 5 months of pregnancy (first 24 weeks of amenorrhea). If this drug is administered to a woman wishing to become pregnant or who is less than 6 months pregnant, the dose should be as low as possible and the duration of treatment as short as possible. Prolonged use is strongly discouraged.
From the beginning of the 6th month (beyond 24 weeks of amenorrhea): any intake of this drug, even punctual, is contraindicated. Inadvertent use after this date warrants cardiac, renal, fetal and/or neonatal monitoring, depending on the term of exposure. The duration of this monitoring should be adapted to the compound's elimination half-life
Breast-feeding
As A.I.N.S. is excreted in breast milk, this drug is not recommended for nursing mothers.
In the event of breast-feeding, this drug should never be applied to the breasts.
Fertility
As with all NSAIDs, the use of this drug may temporarily impair female fertility by affecting ovulation; it is therefore not recommended for women wishing to conceive a child. In women experiencing difficulties conceiving, or undergoing fertility tests, discontinuation of treatment should be considered.
Effects on ability to drive and use machines:
Although the occurrence of such effects is highly unlikely when using skin preparations such as FLECTOR TISSUGEL HEPARINE, patients who have previously experienced dizziness or other Central Nervous System disorders while taking NSAIDs should refrain from driving vehicles or operating machinery.
Composition Flectortissugel Heparin sprain 3 plasters
medicated plaster (white to pale yellow gel spread evenly on a non-woven backing) : Diclofenac epolamine, i.e. Diclofenac sodium 1 g/100 g, Heparin sodium 40,000 IU/100 g.
non-woven backing: Polyester. adhesive layer (active gel) : Gelatin, Povidone K 90, Liquid sorbitol (non-crystallizable), Heavy kaolin, Titanium dioxide (E 171), Propylene glycol, Methyl parahydroxybenzoate (E 218), Propyl parahydroxybenzoate (E 216), Disodium edetate (E 385), Tartaric acid, Aluminium glycinate, Sodium carmellose, Sodium polyacrylate, 1,3-butylene glycol, Polysorbate 80, Parfum Dalin PH, (Propylene glycol, Benzyl salicylate, Phenylethyl alcohol, Alpha amylcinnamic aldehyde, Hydroxycitronellal, Phenylethyl phenylacetate, Cinnamyl acetate, Benzyl acetate, Terpineol, Cinnamic alcohol, Cyclamenaldehyde), Purified water.
protective film: Polypropylene.
Each 10 cm x 14 cm medicated plaster contains 14 g gel containing 140 mg sodium diclofenac as diclofenac epolamine and 5600 IU heparin sodium.
Notable excipients: propylene glycol (420 mg), methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216) and Dalin PH fragrance containing benzyl salicylate, alpha amylcinnamic aldehyde, hydroxycitronellal and cinnamic alcohol.
Flectortissugel Heparin sprain 3 plasters is a medication in plaster form, recommended for ankle sprains.
Flector Tissugel Heparin plasters contain 2 active ingredients:
- Diclofenac epolamine, a non-steroidal anti-inflammatory drug (NSAID) used to soothe pain and reduce inflammation associated with sprains and other injuries.
- Topicalheparin sodium, an anti-inflammatory and anti-oedematous active ingredient.
Directions for use Flectortissugel Sprain Heparin 3 plasters
Dosage
ADULTS: 1 application per day.
Use FLECTOR TISSUGEL HEPARINE for the shortest possible time.
Application of FLECTOR TISSUGEL HEPARINE should not exceed 3 days. If there is no improvement after 3 days, a physician should be consulted.
Pediatric population
In the absence of specific studies, the use of FLECTOR TISSUGEL HEPARINE is not recommended in children.
Elderly
This drug should be used with caution in the elderly (see Warnings and Precautions for Use).
Hepatic or renal insufficiency
For use of FLECTOR TISSUGEL HEPARINE in patients with hepatic or renal insufficiency, see Warnings and Precautions for Use.
Method of administration
Cut the plaster envelope where indicated.
Remove the plaster, peel off the plastic film protecting the adhesive surface and apply the plaster to the painful area or joint. If necessary, the plaster can be held in place with elastic netting.
Close the envelope carefully with the zipper.
The plaster must be used intact.
Precautions for use Flectortissugel Heparin sprain 3 plasters
Contraindications:
Hypersensitivity to the active substance or to any of the excipients listed under Excipients.
- Pregnancy, from the beginning of the 6th month (beyond 24 weeks of amenorrhea) (see Fertility, pregnancy and breast-feeding),
- Injured skin, whatever the lesion: oozing dermatitis, eczema, infected lesions, burns or wounds.
- Patients with active peptic ulcers.
- In children.
Precautions for use:
The plaster must not come into contact with eyes/mucous membranes or be applied to eyes or mucous membranes.
Do not use under an occlusive dressing. However, for the treatment of sprains and strains, a compression bandage may be used.
If you develop a rash after applying FLECTOR TISSUGEL HEPARINE, discontinue treatment immediately.
The concomitant administration of drugs containing diclofenac or other NSAIDs, either topically or systemically, should be avoided.
Although the occurrence of systemic adverse reactions is rare, FLECTOR TISSUGEL HEPARINE should be used with caution in patients with impaired cardiac, renal or hepatic function, and in patients with a history of gastrointestinal ulcers, inflammatory bowel disease or gastrointestinal bleeding. Non-steroidal anti-inflammatory drugs should be used with particular caution in the elderly, who are more prone to adverse reactions.
This medicine contains methyl parahydroxybenzoate and propyl parahydroxybenzoate. It may cause allergic reactions (possibly delayed). This medicine contains 420 mg propylene glycol, which may cause skin irritation.
This medicine contains a fragrance containing the following allergens which may cause allergic reactions: benzyl salicylate, alpha amylcinnamic aldehyde, hydroxycitronellal and cinnamic alcohol. To reduce the risk of photosensitization, patients should be advised to avoid exposure to solar radiation (sunlight or UV booths).
Bronchospasm may occur in patients with bronchial asthma, allergic disease or allergy to acetylsalicylic acid or other NSAIDs, or a history of these conditions. FLECTOR TISSUGEL HEPARINE should be used with caution in patients with or without chronic asthma, in whom attacks of asthma, urticaria or acute rhinitis are provoked by aspirin or other non-steroidal anti-inflammatory drugs (see Contraindications).
Pregnancy and lactation :
Pregnancy
Inhibition of prostaglandin synthesis by NSAIDs may affect the course of pregnancy and/or the development of the embryo or fetus.
Risks associated with 1st trimester use
Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis, following treatment with a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformation increased from less than 1% in the general population, to approximately 1.5% in people exposed to NSAIDs. The risk appears to increase with dose and duration of treatment. In animals, administration of a prostaglandin synthesis inhibitor has been shown to cause increased pre- and post-implantation loss and embryo-fetal lethality. In addition, a higher incidence of certain malformations, including cardiovascular, has been reported in animals given a prostaglandin synthesis inhibitor during the organogenesis phase of gestation.
Risks associated with use from 12 weeks of amenorrhea to birth:
- From the 12th week of amenorrhea until birth, all NSAIDs, by inhibiting prostaglandin synthesis, can expose the fetus to renal impairment:
- in utero, as early as 12 weeks of amenorrhea (start of fetal diuresis): oligohydramnios (usually reversible on discontinuation of treatment), or anohydramnios, particularly with prolonged exposure.
- at birth, renal insufficiency (reversible or not) may persist, particularly in cases of late and prolonged exposure (with a risk of delayed severe hyperkalemia).Risks associated with use beyond the 24th week of amenorrhea and up to birth:
Beyond the 24th week of amenorrhea, NSAIDs may expose the fetus to cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension). Constriction of the ductus arteriosus can occur from the beginning of the 6th month (beyond the 24th week of amenorrhea) and can lead to fetal or neonatal right heart failure, or even fetal death in utero. This risk is all the greater the closer to term the drug is taken (less reversibility). This effect exists even when a single dose is taken.
At the end of pregnancy, both mother and newborn may experience :
- prolonged bleeding time, due to an anti-aggregation action which may occur even after very low doses of the drug have been administered;
- inhibition of uterine contractions, leading to delayed term or prolonged delivery:
Unless absolutely necessary, this drug should not be prescribed to women contemplating pregnancy or during the first 5 months of pregnancy (first 24 weeks of amenorrhea). If this drug is administered to a woman wishing to become pregnant or who is less than 6 months pregnant, the dose should be as low as possible and the duration of treatment as short as possible. Prolonged use is strongly discouraged.
From the beginning of the 6th month (beyond 24 weeks of amenorrhea): any intake of this drug, even punctual, is contraindicated. Inadvertent use after this date warrants cardiac, renal, fetal and/or neonatal monitoring, depending on the term of exposure. The duration of this monitoring should be adapted to the compound's elimination half-life
Breast-feeding
As A.I.N.S. is excreted in breast milk, this drug is not recommended for nursing mothers.
In the event of breast-feeding, this drug should never be applied to the breasts.
Fertility
As with all NSAIDs, the use of this drug may temporarily impair female fertility by affecting ovulation; it is therefore not recommended for women wishing to conceive a child. In women experiencing difficulties conceiving, or undergoing fertility tests, discontinuation of treatment should be considered.
Effects on ability to drive and use machines:
Although the occurrence of such effects is highly unlikely when using skin preparations such as FLECTOR TISSUGEL HEPARINE, patients who have previously experienced dizziness or other Central Nervous System disorders while taking NSAIDs should refrain from driving vehicles or operating machinery.
Composition Flectortissugel Heparin sprain 3 plasters
medicated plaster (white to pale yellow gel spread evenly on a non-woven backing) : Diclofenac epolamine, i.e. Diclofenac sodium 1 g/100 g, Heparin sodium 40,000 IU/100 g.
non-woven backing: Polyester. adhesive layer (active gel) : Gelatin, Povidone K 90, Liquid sorbitol (non-crystallizable), Heavy kaolin, Titanium dioxide (E 171), Propylene glycol, Methyl parahydroxybenzoate (E 218), Propyl parahydroxybenzoate (E 216), Disodium edetate (E 385), Tartaric acid, Aluminium glycinate, Sodium carmellose, Sodium polyacrylate, 1,3-butylene glycol, Polysorbate 80, Parfum Dalin PH, (Propylene glycol, Benzyl salicylate, Phenylethyl alcohol, Alpha amylcinnamic aldehyde, Hydroxycitronellal, Phenylethyl phenylacetate, Cinnamyl acetate, Benzyl acetate, Terpineol, Cinnamic alcohol, Cyclamenaldehyde), Purified water.
protective film: Polypropylene.
Each 10 cm x 14 cm medicated plaster contains 14 g gel containing 140 mg sodium diclofenac as diclofenac epolamine and 5600 IU heparin sodium.
Notable excipients: propylene glycol (420 mg), methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216) and Dalin PH fragrance containing benzyl salicylate, alpha amylcinnamic aldehyde, hydroxycitronellal and cinnamic alcohol.
Français
English
